NMD4C Basic Science Trainee Committee Provides Leadership Opportunity for Next Generation of Neuromuscular Researchers
The NMD4C is excited to announce the nine members of the newly-formed Basic Science Trainee Committee! Representing the interests of trainees within the network, the BSTC offers an opportunity for professional growth for future leaders in neuromuscular research.
Committee Chair Dr Jean-Philippe Leduc-Gaudet shares “The formation of the Basic Science Trainee Committee is an exciting milestone for the NMD4C, providing important leadership opportunities for the next generation of neuromuscular researchers and strengthening the trainee voice within the network’s pre-clinical science activities. I look forward to working with this talented group of trainees to make a lasting impact in the Canadian neuromuscular research community.”
The group will work to communicate the training and professional development needs of trainees to the NMD4C pre-clinical science pillar leads, provide feedback, and suggest improvements to existing NMD4C trainee opportunities. Additionally, the BSTC will work on their own projects to strengthen the collaborative landscape of basic neuromuscular research resources in Canada, including:
- Creating an open-source database of research protocols and expertise from neuromuscular research labs in Canada.
- Implementing individual traineeships to learn specialized techniques.
- Supporting the organization of events, workshops, and activities geared towards trainees that promote professional and personal development.
The BSTC is composed of 9 members, including a chair, co-chair, secretary, and general members, reflective of the diversity of the neuromuscular trainee population in Canada
Meet the Team:
- Dr Jean-Philippe Leduc-Gaudet, Chair
- Dr Emma Sutton, Co-Chair
- Dr Adrien Rihoux, Secretary
- Shatha Atieh
- Jaryeon Lee
- Dr Sean Ng
- Dr Matthew Triolo
- Rebecca Yaworski
Read more about the team and their mandate.
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.